1. Introduction
===============

In Japan, the endoscopic submucosal dissection (ESD) has been considered as a preferred surgical procedure for treatment of early gastric cancer.^\[[@R1]--[@R5]\]^ Notably, ESD tends to induce large iatrogenic artificial ulcers and delayed bleeding complication.^\[[@R1]\]^ Aiming at the ESD-induced ulcers and its complication, proton pump inhibitors (PPIs) are widely prescribed after ESD.^\[[@R6]\]^ In December 2014, vonoprazan (TAK-438), a novel potassium-competitive acid blocker (P-CAB), was approved for clinical use in Japan.^\[[@R7]\]^ The P-CABs inhibit the proton pump enzyme in a reversible and potassium-competitive manner,^\[[@R8]\]^ resulting in a more rapid, potent, and sustained acid inhibitory effect than PPIs.^\[[@R9]\]^ In the preclinical trials, P-CABs were found unaffected by the time of meals and CYP2C19 polymorphism.^\[[@R10]\]^ All the advantages have made vonoprazan into the substitute of PPIs as the 1st-line therapy in eradicating *Helicobacter pylori* (*H pylori*).^\[[@R11]--[@R13]\]^

Some clinical trials and observational studies have compared the effectiveness between vonoprazan and PPIs in curing ESD-induced ulcer\'s scars and preventing delayed bleeding during 2 weeks,^\[[@R14],[@R15]\]^ 4 weeks,^\[[@R14],[@R16]--[@R22]\]^ and 8 weeks.^\[[@R14],[@R16]--[@R18],[@R20],[@R23]--[@R25]\]^ However, the results of the effectiveness are inconsistent and controversial. One clinical trial^\[[@R20]\]^ reported that most ESD-induced ulcers had already healed at 4-week follow-up and implied that the evaluation of drugs at 2 weeks was more crucial. The only meta-analysis^\[[@R26]\]^ had selection bias in controversial studies and did not carry out an analysis of 2 weeks' evaluation.^\[[@R26]\]^ Moreover, 2 clinical trials^\[[@R18],[@R24]\]^ have been published after the systematic review. Thus, it still remains unclear whether vonoprazan is superior to PPIs in healing ESD-induced ulcers and preventing delayed bleeding, especially at 2-week follow-up. The present meta-analysis aims to evaluate the effectiveness of vonoprazan versus PPIs on the treatment of post-ESD ulcers and prevention of delayed bleeding complication.

2. Methods and analyses
=======================

This protocol is reported according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) 2015 checklist.^\[[@R27]\]^ In this protocol, the systematic review and meta-analysis was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.^\[[@R28]\]^ The protocol of this systematic review and meta-analysis has been registered in the international prospective register of systematic reviews (PROSPERO) database, with an identifier CRD42018116855.

2.1. Data sources and search strategies
---------------------------------------

An extensive search will be conducted in PubMed, Cochrane Library, ClinicalTrials.gov, and Google Scholar. The search strategy will include keywords "Vonoprazan", "TAK-438", and "ESD" (Appendix 1). As for unclear reported data, further contact with the original authors will be conducted. Study selection will be conducted in a PRISMA-compliant flow chart (Fig. [1](#F1){ref-type="fig"}).

![PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic review and Meta-Analysis.](medi-98-e14381-g001){#F1}

2.2. Eligibility criteria
-------------------------

The eligible studies will be selected in accordance with the checklist in Appendix 2 and the eligibility criteria were as follows:

### 2.2.1. Study design

Randomized controlled trials (RCTs) and observational studies, such as cohort and case control studies, will be included. Case reports, review articles, preclinical studies, and any other non-relevant studies will be excluded.

### 2.2.2. Follow-up periods

In order to observe changes in the ESD-induced ulcer\'s shrinkage rates or scar stages from the early phase, this meta-analysis will include the RCTs and observational studies with follow-up ≥ 2 weeks.

### 2.2.3. Participants

This meta-analysis will include only the RCTs and observational studies on ESD-induced ulcer patients aged ≥ 18 years.

### 2.2.4. Interventions

This meta-analysis will include only the RCTs and observational studies on vonoprazan monotherapy or vonoprazan combined with mucosal protective agent therapy.

### 2.2.5. Comparators

This meta-analysis will include only the RCTs and observational studies employing PPIs monotherapy or PPIs combined with mucosal protective agent therapy as comparators.

### 2.2.6. Outcomes

This meta-analysis will include only the RCTs and observational studies measuring shrinkage rates of ESD-induced ulcer, the number of people in ESD-induced scar stage, and the number of people with delayed bleeding. The RCTs without all these 3 outcomes will be excluded. Shrinkage rate was defined as: (1 -- ulcer size at 2, 4, or 8 weeks after ESD ÷ initial ulcer size) × 100(%). Scar stage includes: Firstly, S1 and S2 stage ulcer in accordance with Sakita-Miwa classification^\[[@R29]\]^ or secondly, at least 90% shrinkage rate at 4-week follow-up and 100% shrinkage rate at 8-week follow-up. Delayed bleeding was defined as the decline in the hemoglobin level ≥2 g/dL.

2.3. Study selection
--------------------

Two reviewers will use the same eligibility evaluation form to evaluate the RCTs and observational studies. Disagreement of their evaluation will be discussed with the help of a third investigator.

2.4. Data extraction
--------------------

Data will be extracted by 1 reviewer and verified by another. In addition to the outcomes, the characteristics will be extracted as follows: First, authors and publication year. Second, interventions (dose of vonoprazan, PPIs, and mucosal protective agent). Third, baseline characteristics of participants. Fourth, follow-up periods. Fifth, study designs. Sixth, findings. The extracted data will be displayed in Appendix 3 for further analysis.

2.5. Quality assessment
-----------------------

The Cochrane risk of bias tool^\[[@R30]\]^ (Appendix 4) will be used to assess the design, conduction, and outcomes of the included RCTs. The Newcastle-Ottawa Quality Assessment Scale^\[[@R31]\]^ (Appendix 5) will be used to assess the selection, comparability, and outcome of the observational studies. The quality of each study will be assessed by 1 reviewer and verified by another. The quality of evidence will be determined with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.^\[[@R32]\]^ The analysis will be conducted with GRADE profiler.

2.6. Data synthesis and analysis
--------------------------------

This meta-analysis based on the random-effects model will be conducted by using RevMan version 5.3.^\[[@R33]\]^ For shrinkage rates, the effect will be measured as mean difference with 95% confidence intervals (CIs). Outcomes such as the number of patients in scar stage and delayed bleeding will be presented as OR with 95% CIs. Funnel plots and Egger\'s regression test will be implemented for publication bias evaluation. The *I*^*2*^ statistic, which describes the variations across trials rather than to sampling errors, will be calculated for heterogeneity assessment. The *I*^*2*^ values of 25, 50, and 75% indicated low, medium, and high heterogeneity. Statistical significance will be set at *P* \< .05 for all analyses.

2.7. Sensitivity analysis
-------------------------

To evaluate the robustness of this meta-analysis results, sensitivity analysis will be performed by excluding the trials with mucosal protective agent combined therapy and high risk of bias (if any). We would claim this meta-analysis to be robust or reliable if the sensitivity analysis has no significant change from the results.

2.8. Ethical issues
-------------------

This meta-analysis is a literature study, and there is no direct contact with patients. Therefore, this study does not require ethical issues approval.

3. Discussion
=============

This meta-analysis will discuss the effectiveness of vonoprazan versus PPIs on curing ESD-induced ulcers and preventing delayed bleeding at different follow-up periods, especially at 2-week follow-up. The evidence would be useful for clinicians, patients, and policy-makers regarding the treatment of ESD-induced ulcers and prevention of post-ESD bleeding.
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